No headlines found.
No press releases found.
No news found.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Mustang Bio trades on the NASDAQ stock market under the symbol MBIO.
As of October 5, 2026, MBIO stock price declined to $0.46 with 14,443 million shares trading.
MBIO has a beta of 1.68, meaning it tends to be more sensitive to market movements. MBIO has a correlation of 0.12 to the broad based SPY ETF.
MBIO has a market cap of $3.49 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, MBIO traded as high as $105.50 and as low as $.46.
The top ETF exchange traded funds that MBIO belongs to (by Net Assets): VXF.
MBIO has underperformed the market in the last year with a price return of -70.9% while the SPY ETF gained +16.9%. MBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.6% and -14.7%, respectively, while the SPY returned +4.3% and +1.7%, respectively.
MBIO support price is $.45 and resistance is $.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBIO shares will trade within this expected range on the day.
